RLMD

Relmada Therapeutics, Inc.

Healthcare
Biotechnology
$474M market cap

Forecast run · Sep 14, 2026Upside rank 305 of 3,136

Model Signal

ForecastQ Daily Probabilities

61.9%

45.1%

46.3%

Analyst Consensus

Recommendation2.50/5 Buy

Last price$4.52

Price target$12.00

Implied move+165.5%

Analysts8

ForecastQ Portfolios

RLMD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.